Epigenetic Targets for the Treatment of Human Diseases
All welcome.
Rab Prinjha currently leads the Epinova Epigenetics DPU in the Immuno-Inflammation therapy area (II-TA) and is co-chair of the GSK Biology Council. Prior to this he led the Target Progression department with responsibilities for target selection, validation and epigenetic compound characterisation along with coordinating academic collaborations. He joined Epinova from the II-virtual group which was responsible for implementing the externalisation and portfolio diversification strategy of the TA. Previously he led a Target Validation group in the Neurology CEDD focussed on neurodegeneration. In addition to advancing many programs while in Neurology he cloned a novel inhibitor of CNS regeneration called Nogo-A and led this program from gene cloning to Candidate Selection and into clinical trials. Rab joined GSK from academia including a post-doc in developmental neuroscience at Guy’s Hospital and PhD in molecular biology of the cell cytoskeleton at UCL.
Date: 5 October 2016, 13:00 (Wednesday, 0th week, Michaelmas 2016)
Venue: NDM Building, Headington OX3 7FZ
Venue Details: TDI Basement seminar room
Speaker: Rab Prinjha (GSK Biology Council)
Organising department: Structural Genomics Consortium
Organiser: Natsumi Astley (University of Oxford )
Organiser contact email address: natsumi.astley@sgc.ox.ac.uk
Part of: SGC Seminars
Booking required?: Not required
Audience: Public
Editor: Natsumi Astley